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Misoprostol
Postpartum hemorrhage
Prevention
TreatmentClinical and operational evidence indicates that misoprostol is a safe and effective technology for addressing
postpartum hemorrhage, a major cause of maternal death. This research has not yet been translated into
effective policies, programs, and practice in many parts of the world. Efforts to expand evidence-based use
of misoprostol are often complicated by misoprostol's range of indications, insufﬁcient availability, a lack of
evidence-based guidelines and provider training, and misconceptions about the drug. The medical and health
policy communities need to work together to translate research ﬁndings into changes in policy, knowledge,
and clinical practice so that we can deliver on the world's promise to improve maternal health.
© 2011 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.1. Introduction
As the global community strives to deliver on Millennium Devel-
opment Goal (MDG) 5's promise to improve maternal health, evi-
dence is growing of misoprostol's value in addressing the global
burden of postpartum hemorrhage (PPH), the leading cause of mater-
nal death in low-resource regions of the world. In March 2011, miso-
prostol was added to the WHO Model List of Essential Medicines for
the prevention of PPH, validating its important role for women's
health and survival [1]. Misoprostol has also been added to many
global and national clinical guidelines (such as FIGO/ICM [2], ACOG
[3], and RCOG [4], among others) for addressing PPH. These develop-
ments reﬂect a growing consensus that misoprostol is a safe and
effective option for preventing and treating PPH, particularly in set-
tings where oxytocin—the gold standard drug—is not available or
where its administration is not feasible.
Emerging research has provided compelling evidence of misopros-
tol's potential to prevent and treat PPH, and has established its safety
and efﬁcacy, and its acceptability to women. We now know that:
• Oral misoprostol (600 μg) can be safely and effectively adminis-
tered by lower-level health providers to prevent PPH [5,6].
• Sublingual misoprostol (800 μg) is a safe and effective treatment for
women experiencing PPH [7,8].
• Adjunct use of misoprostol (i.e. simultaneous treatment with miso-
prostol in addition to oxytocin) provides no additional beneﬁt for
women who are receiving oxytocin to treat PPH and results in in-
creased adverse effects [9].03, New York, NY 10012 USA.
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eration of Gynecology and Obstetrics.• Misoprostol has the potential to address coverage gaps and
provide logistical advantages in both facility and community set-
tings (Box 1).
However, this growing body of research has yet to be translated into
effective policies, programs, and practice inmany parts of theworld.We
have the evidence. Our challenge now is to use the evidence of miso-
prostol's efﬁcacy and safety to ensure that every woman has access to
a uterotonic for prevention and/or treatment of PPH.
Efforts to broaden women's access to misoprostol face signiﬁcant
and unique challenges. In contrast to the situation with new pharma-
ceutical products, the widespread introduction of misoprostol is both
facilitated and complicated by the drug's history and the policy envi-
ronments that govern its use. Because it has been used ad hoc for over
30 years, many providers have experience with misoprostol. Those
who have used it safely and effectively in the past are often highly
supportive of its wider use; those who have witnessed its misuse—
for example, the administration of dangerously high dosages for in-
duction of labor—may take a more negative view. Furthermore, miso-
prostol's effectiveness for a variety of indications (Box 2) can provide
opportunities for its wide-scale adoption, but may also (particularly
in terms of its association with abortion) engender discomfort and re-
sistance among policy makers and providers, and outright opposition
from antiabortion activists. Lastly, as misoprostol is not a new drug, it
may beneﬁt from existing pathways to introduction, but must also
overcome a history of controversy.
2. Challenges to evidence-based use of misoprostol
2.1. Use for a range of indications
Misoprostol has a range of uses and indications in reproductive
health (Box 2). In some parts of the world, this potential has resultedPublished by Elsevier Ireland Ltd. All rights reserved.
Box 1
Advantages of misoprostol.
• Stable at room temperature
• Easy to store and administer
• Inexpensive
• Widely available
ox 2
omen's heath indications for misoprostol.
• Cervical priming
• Induced abortion
• Labor induction
• Uterine evacuation after failed pregnancy
• Prevention and treatment of PPH
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Misoprostol's use as an abortifacient and the incorrect, mistimed, or
overly aggressive use of misoprostol for inducing labor have often
stymied efforts to promote its use for PPH.
It is important that practitioners, policy makers, and advocates
work together to ensure that concerns about misoprostol's use
for other indications do not lead to limitations on its availability
for PPH.
2.2. Availability and registration of misoprostol
Considerable attention has been focused in the past few years on
registering misoprostol speciﬁcally for the prevention and/or treat-
ment of PPH, as a step toward increasing its availability for PPH. How-
ever, registration for a speciﬁc use is neither necessary nor sufﬁcient
to ensure availability for that medical condition. Indeed, “not regis-
tered” is not equivalent to “inappropriate,” “dangerous,” or “ineffec-
tive.” Many drugs are not registered for indications for which there
is substantial evidence of safety and effectiveness. “Not registered”
simply means a marketing agreement is not in place permitting pro-
motion and sale of the drug for that particular indication. Off-label
use is common and is sanctioned by stringent regulatory agencies in
many parts of the world as an effective way for providers to follow
evidence-based practices. Furthermore, governments are not behold-
en to commercial registration and can choose to make a product
available if it has a public health beneﬁt.
While pursuing registration may in some cases be a useful strat-
egy for increasing availability of misoprostol, the importance of this
strategy depends on the context. In some countries, no misoprostol
products are registered, yet it is widely available; conversely, in
other countries there are registered products that cannot be found
on any pharmacy shelves. In many countries, misoprostol is com-
mercially registered only for its original indication of preventing
gastric ulcers; often, this product can be used off-label for PPH.
Whether or not pursuing registration speciﬁcally for PPH is neces-
sary depends on government policies and regulations in each coun-
try. Advocacy to improve the availability of misoprostol on a
national level may involve pursuing registration, promoting inclu-
sion on the national essential medicine list, both, or neither; it is im-
portant to bear in mind that the utility of each of these steps is
context speciﬁc. [10]
2.3. Lack of evidence-based guidelines and provider training
A product's availability does not ensure its appropriate use.
When labels for registered products do not reﬂect the current evi-
dence, clinical guidelines can correct for this problem by gathering,
interpreting, and disseminating emerging evidence. Unfortunately,
national clinical guidelines are often slow to reﬂect the latest re-
search, hampering efforts to provide the most effective evidence-
based health care. This is an issue particularly with regard to miso-
prostol due to the dearth of clear and consistent usage guidance.
As a result, misoprostol is often used with outdated, nonevidence-
based protocols.B
WEvidence-based guidelines for the use of misoprostol for PPH need to
be put in place at the national level, and this must be supplemented
by training and ongoing education of providers. Since this drug can
be used for multiple indications, training must include clear dosing
information, including the routes and precautions associated with
each type of use.2.4. Misconceptions and misperceptions
There remain concerns, often unsupported by available evidence,
about misoprostol's distribution and use at the community level and
with home deliveries. Some policy makers worry that promotion of
misoprostol for use in nonfacility deliveries may deter women from
seeking care at facilities with skilled providers. In a world where
barely half of women in low-resource countries give birth with a
skilled attendant, these concerns—while understandable—ignore the
harsh reality faced by women in low-resource settings: that skilled,
facility-based childbirth care is often not accessible. In seeking to en-
sure that all women—regardless of where they give birth—have ac-
cess to uterotonics for prevention and treatment of PPH, countries
should be supported in pursuing complementary, mutually-
supportive strategies. For example, the government of Nepal's strate-
gy for preventing PPH is to promote active management of the third
stage of labor in facilities and the use of misoprostol at home births.
More evidence on the impact of community distribution of misopros-
tol on rates of facility-based delivery will be useful, but it is important
that the goals of protecting women's lives and health from uncon-
trolled hemorrhage and of providing skilled care for every woman
are not placed in conﬂict with one another. Rather, policies and prac-
tices must approach these issues as complementary.
There are also perceptions that, if misoprostol is made more wide-
ly available for use with PPH, it will be repurposed for use in medical
abortion, thereby increasing the number of abortions. Based on these
fears—which are unsupported by the evidence—policy makers in
some countries have placed restrictions on misoprostol's availability.
In some Latin American countries, for instance, only physicians are le-
gally permitted to prescribe misoprostol. Because a large number of
deliveries are attended by nurses and midwives, this policy either
limits women's access to medicines they need to protect their lives
and health, or it creates a direct conﬂict between law and clinical
practice. Those who wish to restrict women's right to reproductive
choice should not be permitted to limit access to a safe, effective,
and practical drug for managing PPH.
Experience has shown that obstetricians and gynecologists can be
particularly compelling advocates on these issues. In countries
where advances in community-level access to misoprostol offer the
promise of reducing mortality and morbidity from PPH, national ob-
stetrics and gynecology associations have played an important advo-
cacy role. Recognizing the current undersupply of skilled physicians,
as well as the lack of well-equipped facilities offering basic and ad-
vanced obstetric care, physicians have been leaders in efforts to de-
velop innovative and effective ways of ensuring universal access to
uterotonics. [11]
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3.1. Disseminate research
Transforming research ﬁndings into effective changes in policy,
knowledge, and clinical practice requires a number of mutually-
reinforcing strategies:
• Identifying champions, who can share research with a broad range
of audiences and inﬂuence policies, future research, facility-level
clinical practice, and clinicians’ behavior.
• Providing regular technical updates, through workshops, publica-
tions, and other mechanisms to share the latest scientiﬁc informa-
tion and evidence.
3.2. Share experiences
Country-to-country exchange of experience is crucial for addres-
sing misconceptions related to increased access to and use of miso-
prostol. Results of research, operations studies, or pilot programs
conducted in one country can, if shared effectively, have a positive in-
ﬂuence in many others. It is thus important to share experiences and
best practices at the regional level.
3.3. Engage professional associations as partners
Professional associations, including obstetrics/gynecology and
midwifery societies, are key partners in providing accurate informa-
tion about the use of misoprostol for PPH to policy makers and
other stakeholders. Giving health providers (including midlevel/com-
munity providers) accurate, updated information will help to ensure
that all women receive high-quality maternal health care. A good ex-
ample of professional leadership is the 2011 Special Editorial pub-
lished in the IJGO by FIGO Chief Executive Professor Hamid
Rushwan, which calls attention to misoprostol's importance for PPH
and the related work FIGO plans to undertake [12]. FIGO is a key part-
ner of an initiative led by Gynuity Health Projects to develop and
translate evidence on the role of misoprostol in PPH prevention and
treatment.
4. Conclusion
Misoprostol has emerged as a promising technology for addres-
sing the global burden of PPH; however, we must remember that it
is not a panacea. No drug can replace the need for strengthened
basic and emergency obstetric care services; for more and better-
trained health workers; for clean, well-equipped facilities; and for
culturally-sensitive, high-quality maternal health care. Rather, miso-
prostol must be viewed as one strategy among many—albeit onethat can help to address some of the stubborn challenges faced by
health systems and facilities that still lack consistent electricity, cold
storage, trained providers, and/or intravenous therapy. As we work
together to reduce the suffering and mortality caused by PPH around
the world, we should keep our ultimate goal in sight: ensuring that
every woman has access to a uterotonic for effective management
of PPH; that every woman can beneﬁt from advances in medical tech-
nology and knowledge; and that every woman receives the skilled,
high-quality obstetric care that is her right and the world's obligation.
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